| Mar 2008 | 2007 | 2006 | |||||
|---|---|---|---|---|---|---|---|
| Total Revenues ($Mil): | 7.12 | 7.03 | 4.13 | ||||
| Depreciation & Amort ($Mil): | 1.13 | 1.13 | 0.84 | ||||
| Operating Income ($Mil): | -23.03 | -27.19 | -16.27 | ||||
| Net Income ($Mil): | 9.61 | -24.58 | -17.06 | ||||
| Earnings Per Share ($): | 0.44 | -1.37 | -1.62 | ||||
| Dividends ($): | 0.00 | 0.00 | 0.00 |
| Mar 2008 | 2007 | 2006 | |||||
|---|---|---|---|---|---|---|---|
| Current Assets ($Mil): | 36.01 | 32.98 | 53.91 | ||||
| Current Liabilities ($Mil): | 9.03 | 9.25 | 5.34 | ||||
| Long Term Debt ($Mil): | 0.00 | 0.00 | 0.00 | ||||
| Shares Outstanding (000): | 18360 | 18340 | 15630 | 0 | 0 | 0 | 0 |
| Common Equity ($Mil): | 92.37 | 62.45 | 45.00 |
| Mar 2008 | 2007 | 2006 | |||||
|---|---|---|---|---|---|---|---|
| Profit Margin (%): | 134.97 | -349.64 | -413.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Return on Equity (%): | 12.82 | -39.36 | -37.91 | 0.00 | 0.00 | 0.00 | 0.00 |
| Return on Assets (%): | 10 | -27.43 | -26.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| P/E Ratio: | 25 | -11.19 | -13.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price/Book: | 3 | 4.50 | 7.33 | NaN | NaN | NaN | NaN |
| Debt Equity: | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage: | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book Value ($): | 5.03 | 3.41 | 2.88 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price/Sales: | 37.72 | 26.82 | 79.82 | NaN | NaN | NaN | NaN |
| Dividend Payout (%): | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |

| AMGEN | +35.10 | 62.51 | |
| GILEAD SCIENCES | +23.70 | 50.28 | |
| AMYLIN PHARMA I | -55.60 | 21.57 | |
| BIOGEN IDEC INC | -16.40 | 50.34 | |
| GENENTECH INC | +37.10 | 98.29 |
